FDA unannounced inspections India infographic showing 87% of audits unannounced in FY2026

FDA unannounced inspections in India have become the norm: 87% of the US regulator’s drug facility audits in India in fiscal 2026 were carried out without advance notice, up from 47% a year earlier, according to figures presented by FDA associate commissioner Elizabeth Miller and reported by RAPS and Bloomberg this month. In China the share rose from 19% to 61%. For Indian manufacturers, which supply about 40% of the generic medicines sold in the US, it means every working day now has to be inspection-ready.

Key takeaways on FDA unannounced inspections in India

  • Nearly nine in ten FDA drug inspections in India are now unannounced, versus under half the previous year.
  • The policy follows the FDA’s May 2025 decision to expand surprise inspections of foreign food and medical product sites.
  • India hosts the largest number of FDA-registered drug facilities outside the US and accounted for 34% of sites the FDA inspected for drug quality in fiscal 2024.
  • Inspections used to be coordinated with Indian authorities or arranged in advance; now inspectors can arrive with little or no warning.
  • The FDA says the aim is to see normal operating conditions and treat foreign and US plants alike.

From pre-announced visits to surprise audits

For years, US plants could be inspected without notice while overseas sites usually received weeks of warning, partly because of visa, travel and security logistics. Critics, including US lawmakers, argued that gap let some foreign factories tidy up before inspectors arrived. In May 2025 the FDA said it would expand unannounced foreign inspections. The fiscal 2026 numbers show that policy is now fully in effect in India.

Speaking at the AAM GRx+Biosims conference, Miller said the intent was to see facilities as they normally run: “The point is not to surprise for surprise’s sake.” She also acknowledged practical hurdles, including staff visas, laboratory support and safe security conditions. At a separate event in Mumbai, FDA international relations specialist Neil Bonzagni said the agency now assesses supply chains from raw materials through manufacturing to distribution.

CountryUnannounced share, FY2025Unannounced share, FY2026Change (by our calculation)
India47%87%+40 percentage points
China19%61%+42 percentage points
Source: FDA Office of Inspections and Investigations data as reported by RAPS (November 2026).

Why India is in focus

The scale of India’s exposure explains the attention. In fiscal 2024, more than 62% of FDA drug quality inspections took place outside the US, an all-time high, and India was the single largest location at 34% of inspected sites, ahead of China (28%) and the US itself (24%).

Past quality failures have also shaped the debate. Cough syrups made in India were linked to the deaths of dozens of children in Gambia and Uzbekistan in 2022 and 2023, and contaminated eye drops imported from an Indian maker were tied to four deaths in the US in 2023. More recent cases, such as the Eugia vancomycin recall over a glass particle, show how a single lot problem can quickly become a US regulatory issue.

What it means for Indian drugmakers

An unannounced inspection removes the preparation window that some sites relied on. In practice, companies exporting to the US are likely to focus on:

  • Data integrity: complete, contemporaneous batch and laboratory records, since gaps are among the most common reasons for FDA warning letters to Indian plants.
  • Continuous readiness: cleaning, environmental monitoring and deviation handling that hold up on any given day, not just during scheduled audits.
  • Supplier oversight: traceability for active ingredients and excipients, given the FDA’s end-to-end supply chain view.
  • Staff training: front-line teams who can answer inspectors’ questions without senior quality staff present.

The stakes are commercial as well as regulatory. A poor inspection outcome can lead to a Form 483, a warning letter or an import alert, which can block shipments and delay approvals for new products from the same site. That matters as Indian firms bet on new growth areas, from generic semaglutide (see our report on Aspen’s India-made semaglutide approvals) to biosimilars. The FDA plans biosimilar outreach sessions in New Delhi and Hyderabad in May 2027.

Market context: generics

Acumen Research and Consulting projected that the global generic drugs market would grow at about 11.1% a year from 2020 to reach around USD 627.6 billion by 2027, with North America the largest revenue region. Acumen also notes that generics saved Medicare and Medicaid USD 77 billion and USD 37.9 billion respectively in 2016. These figures were last updated in April 2021, so they are dated and indicative only, but they show how central low-cost generics, many of them made in India, are to US drug spending.

What to watch

  • Whether warning letters and import alerts for Indian sites rise in fiscal 2027 as surprise inspections become routine.
  • How the FDA manages inspector visas and staffing, which Miller flagged as constraints.
  • Indian regulators’ parallel push on manufacturing standards, including the revised Schedule M good manufacturing practice rules for domestic firms.

Frequently asked questions

What is an unannounced FDA inspection?

It is a facility inspection where the FDA gives no advance notice, or very short notice, so inspectors can see normal operations rather than a prepared site.

How many FDA inspections in India are unannounced?

87% in fiscal 2026, up from 47% in fiscal 2025, according to FDA data reported by RAPS.

Does this affect medicines sold in India?

Indirectly. FDA inspections cover plants making products for the US, but many of the same sites also supply India and other markets, so quality upgrades usually apply across a facility.

Sources: RAPS report on FDA Office of Inspections and Investigations data and Bloomberg via News India Times (18 November 2026). Market data: Acumen Research and Consulting. More in Pharmaceutical. Not medical or investment advice. Last updated 19 November 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

2 thoughts on “FDA Unannounced Inspections in India Jump to 87%: What It Means for Indian Drugmakers”

Leave a Reply

Your email address will not be published. Required fields are marked *